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Summary 
Nearly nine-tenths of 27 biopsied intravenous drug abusers showed evidence of non-A non-B 
hepatitis. In between two-thirds and four-fifths non-A non-B infection was the initial viral 
insult to the liver. 
 Persons with known HBV infection and viral hepatitis cannot be assumed to suffer 
from HBV associated liver disease. Vaccination of drug addicts with inactivated HBsAG will 
not preclude them from developing chronic liver disease. 
There is evidence among haemophiliacs that chronic hepatitis previously assumed to have 
been attributable to hepatitis B virus (HBV) is more likely to have been due to other, non-A 
non-B hepatitis viruses.1 In a recent study on the Delta agent and liver disease we have 
compared hepatitis B serology and histology in 27 parenteral drug abusers2 and this has 
afforded us the opportunity to assess the likelihood of a non-A non-B origin to the hepatitis in 
these patients. We report this assessment in this paper. 
Patients and Methods 
Twenty-seven parenteral drug abusers admitted to hospital for liver biopsy during the period 
January 1st to August 31st 1981 are included in this study. At this time an epidemic of 
hepatitis B was in progress among drug abusers in Dublin.3 All patients who were admitted 
with clinically acute hepatitis were asked the duration of intravenous drug abuse and if they 
had been jaundiced since or prior to the onset of such abuse. 
 Patients had the following laboratory investigations performed: Full blood count, 
platlet count, prothrombin time, serum bilirubin, serum alanine and aspartate transaminases 
(SCOT, SGPT), alkaline phosphatase, serum proteins and albumin. Serological tests for HBV 
markers were performed as follows: radioimmunoassay (RIA) for hepatitis B surface antigen 
(HBsAg) (Ausria 11, Abbott), immunodiffusion (ID) for anti-HBs,4, semi-micro ID for HBsAg 
and anti-HBe; and RIA and enzymeimmunoassay for hepatitis B core antibody (anti-HBegG) 
(Corab, Corzyme, Abbott). 
 Tests for IgM antibody to hepatitis A virus were carried out by RIA (Havab M, 
Abbott). Patients negative for HBsAg and by Havab M were also tested for IgM anti-HBs by 
RIA. 
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 HBV serology was taken 10 indicate acute HBV infection if the patient cleared HBsAg 
within four months and HBsAg within two weeks and/or seroconverted to anti-HBe. If HBsAg 
persisted at similar levels for more than six months the patient was defined as being 
chronically infected with HBV. 
 Liver biopsies were carried out using a Menghini needle. Histological diagnosis was 
made in accordance with the criteria suggested by an International Group in 1977.5 
 Where biochemistry was serially repeated and the serum aspartate transaminase 
(SGPT) fell and rose again by a factor of at least two, or a factor of three if it had previously 
returned to normal (| 45 i.u./l) a further transaminase peak was deemed to have occurred. 
Non-A non-B viral infection was assumed to have contributed to the histological findings if 
tests for hepatitis A were negative, and (a) the histological findings were of chronic hepatitis 
in the presence of acute HBV serology; or (b) all tests for HBV markers were negative or (c) 
the histology was of acute hepatitis in the presence of chronic or static HBV serology (IgM 
anti-HBc negative). Two or more peaks of SGPT were taken as supportive evidence of non-A 
non-B infection.6 
 A conclusion as to the virus(es) deemed causally related to the histological findings 
was derived for each patient. 
 Results 
Of the 27 patients 22 were male; their ages ranged from 12 (mean 20.8) to 29 years. The 
duration of intravenous drug abuse was from six (mean 33.6) to i20 months. Three patients 
had a history of previous jaundice since the onset of drug abuse; none gave a history of 
jaundice prior to the onset of abuse. The serological biochemical and initial histological 
findings and the conclusions concerning the viral origin of the patients’ histological hepatitis 
are shown in the table. Eight patients had a second liver biopsy six or more months after the 
first and three patients had three liver biopsies at intervals of at least six months. All eleven 
repeat liver biopsies showed chronic disease, either persistent or active, in agreement with the 
first biopsy. These results show that non-A non-B virus infection contributed to the hepatitis 
in 23 (85%) or 24 (89%) of the 27 patients. Furthermore in between 19 (70%) and 22 (81%) 
of the patients non-A non-B infection was the initial viral insult to the liver. 
 Discussion 
The findings in this study are similar to those of Craske who showed that a proportion of 
hepatitis in haemophiliacs was of non-A non-B origin of at least two serotypes1, the main 
complication of which was persistently abnormal transaminase levels, a finding common with 
non-A, non-B post-transfusion hepatitis (PTH).8 Therefore, it should no longer be assumed 
that chronic viral hepatitis in the presence of known hepatitis B infection is caused by such 
infection. This does not exclude a long-term additive effect of HBV infection with non-A 
non-B which may influence the progression of chronic persistent to chronic active hepatitis, 
the development of cirrhosis or the ultimate risk of hepatoma. Equally several types of non-A 
non-B hepatitis may act synergistically. 
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Table 1 
Serological, Biochemical and Histological Findings and Conclusions as to Viral Origin of 
Hepatitis 
Patient No. Initials Sex 1981 
HBV 
Serology 
No. of 
SGPT 
Peaks 
Histology Conclusions 
1. C.S. M Acute 3 CPH X 3 B on NANB 
2. A.D. M Acute 2 CPH X 3 B on NANB 
3. J.A. F Acute Insf. CPH X 3 B on NANB 
4. D.W. M Acute 2 CPH B on NANB 
5. J.J. M Acute Insf. Acute B 
6. M.McC M Acute Insf. CPH B on NANB 
7. A.C. M Chronic 2 CPH B _ NANB 
8. J.P.B. M + Insf. Insf. CAH Prob. B 
9. J.T. M + Insf. Insf. CAH B on NANB or NANB 
on B 
10. D.C. F Acute Insf. CAH B on NANB 
11. J.F. M Acute Insf. CAH B on NANB 
12. J.D. F + Insf. Insf. CPH X 3 B on NANB or NANB 
on B 
13. E.F. M Acute Insf. CPH B on NANB 
14. J.O’C. M Acute 2 CPH B on NANB 
15. B.J. M Acute B 2 CPH B on NANB 
16. J.C. M Acute 2 Acute B on NANB 
17. P.M. M Acute Insf. CPH B on NANB 
18. R.F. M Acute Insf. CPH X 2 B on NANB 
19. M.C.++ M Acute Insf. CPH B on NANB 
20. G.H. M Acute 2 Acute B 
21. L.M. F Acute 2 CPH B on NANB 
22. M.C. M Acute 2 CPH B on NANB 
23. M.H. M Chronic Insf. Acute NANB on B 
24. D.J. M +++Anti-HBc Insf. CPH NANB on B 
25. M.O’S. M Anti-HBc Insf. CPH NANB on NANB or B 
26. M.McC. F Anti-HBc Insf. Acute NANB 
27. M.F. M All Neg. Insf. CPH NANB on NANB 
 +HBsAG positive but only one attendance. ++Also had acute B negative hepatitis in 1979. 
+++IgM anti-HBC positive in low litre. Insf. = Insufficient data 
 It has been argued that one cannot distinguish histologically between acute and chronic 
hepatitis during acute HBV infection.7 However, it is our experience, both in this study and 
previously9,10, that initially diagnosed chronic liver disease remains chronic. We therefore 
believe that the conclusion that non-A, non-B infection makes a significant contribution to the 
chronic liver disease found in these parenteral drug abusers is valid. 
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 Non-A non-B infection preceded HBV infection in between two-thirds and four-Fifths 
of patients. This can be deduced because in these cases the HBV serology was typically that 
of acute hepatitis B on histologically established chronic liver disease. However, only three 
patients had a history of previous overt hepatitis; since non-A non-B PTH is frequently mild 
or asymptomatic8, this is perhaps not surprising. We do not believe that the Delta infection 
which we have previously reported on a high proportion of these patients2 has contributed to 
the histology at the present time because the predominant marker was Delta antigenaemia 
which is found in primary Delta infection concurrent with hepatitis B. Rarely hepatitis B 
infection has occurred where all HBV serology was negative but HBV markers had been 
found in the liver by immunefluorescence11; we did not test for HBV markers in the liver in 
this study, but the rarity of this finding suggests that our results cannot account for our one 
patient (No. 27) of chronic persistent hepatitis with no HBV markers and clinically acute 
hepatitis. Indeed, this case may well be of acute non-A non-B infection on chronic non-A 
non-B liver disease of different type. Patient No. 25 may also represent acute non-A non-B on 
chronic non-A non-B infection. This type of infection does not appear to have been 
previously described. Except for Delta agent it will not be possible to serologically confirm 
the existence of underlying non-A non-B chronic liver disease in patients until specific tests 
for non-A non-B agents become available. 
 This study suggests that vaccination of drug abusers with inactivated HBsAG will not 
prevent the development of chronic liver disease amongst such abusers; vaccines for non-A 
non-B viruses will also be required. It may, however, slow the progression of such chronic 
liver disease and lessen the risk of subsequent cirrhosis or hepatoma. 
 Acknowledgement 
The authors wish to thank Dr. Richard Tedder, Middlesex Hospital, London, for the IgM 
specific anti-HBs tests. 
References 
1. Craske J. The epidemiology of Factor VIII and IX associated hepatitis in the United 
Kingdom. Med Lab Sci 1981; 38: 430. 
2. Shattock AG, Arthurs Yvonne, Doyle GD, Fielding JF. Hepatitis B virus (HBV) 
associated Delia agent and liver histology in parenteral drug abusers. Dig Dis Sci 1982; 
In Press. 
3. Shattock AG, Kelly MG. Fielding JF, Arthurs Yvonne. Epidemic hepatitis B with Delta 
antigenaemia among Dublin drug abusers. Irish Jour Med Sci 1982; In Press. 
4. Shattock AG. Hepatitis associated (Austrobic) antigen in the Republic of Ireland: A 
preliminary report. Irish J Med Sci 1974: 143: 162-7. 
5. Review by an International Group. Acute and chronic hepatitis revisited. Lancet 1977; 
2: 914-9. 
6. Purcell RH. The hepatitis viruses: An overview and histological perspective. In 
Szmuness W, Alter HJ, Maynard JE, eds. Viral Hepatitis Philadelphia. Franklin 
Institute Press 1981: 9. 
7. Scheucr PJ. Chronic hepatitis: A problem for the pathologist. Histopathology 1977; 1: 
5-19. 
8. Bach RD, Kahn RA. Post-transfusion hepatitis: Current perspectives. Ann Intern Med 
1980; 92: 539-46. 
9. Arthurs Yvonne. Doyle GD, Fielding JF. The course of chronic persistent hepatitis. 
Irish J Med Sci 1982; 151: 83-5. 
10. Arthurs Yvonne, Doyle CD. Fielding JF. The course of chronic active hepatitis. Irish J 
Med Sci 1982; In Press. 
11. Weigand K, Zimmerman A, Schcurer U. Buckhardf F. Hepatitis B virus infection with 
negative HBV serology. Lancet 1982; 2: 551. 
This article is a reproduction of that published in: Irish Medical Journal, October 1983, 76(10) pp.414-415.  
Pagination may not match that of the original. 
This article is a reproduction of that published in: Irish Medical Journal, October 1983, 76(10) pp.414-415.  
Pagination may not match that of the original. 
Requests for reprints to Dr. John F. Fielding, Dept. of Medicine and Gastroenterology. The 
Charitable Infirmary, Jervis St., Dublin 1. 
